Ablation of abnormal areas of epicardial late activation in the RV can suppress recur- rent VA as shown in a small number of In these reports, the spontaneous type 1 Brugada pat- tern on ECG may be eliminated in >75% of patients, and recurrences of VT/VF are markedly Experience and follow-up after ablation are limited, and an ICD for patients who have had syncope or SCA is recommended. A series of patients with Brugada syndrome treated with quinidine had no deaths during a mean follow-up of over 9 years, although adverse effects of quinidine were reported in 38% of patients, these authors felt that quinidine could be used as an alternative to the ICD in selected 4. Observational studies show that quinidine can suppress VF storm in patients with Brugada syn- drome, and a low risk of arrhythmia was observed in a long-term observational study.7.9.1.3-7 No patient treated with quinidine experienced SCD. Adverse effects of quinidine occur in up to 37% of patients. Catheter ablation targeting the epicardial right ventricular areas of abnormality has also been shown to reduce recurrent VF epi- sodes and normalize the ECG.7.9.1.3-9 7.9.1.3-11 5. Administration of procainamide, flecainide, or ajmaline may be useful to provoke type 1 ST elevation in patients suspected to have Brugada syndrome as a cause of symptoms but who do not have a type 1 electrocardiographic pattern at baseline. 